Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Weekly shot shows promise for shedding pounds in obesity trial

NCT ID NCT06662539

Disease control Sponsor: Zealand Pharma Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new weekly injection called petrelintide to help people with obesity or overweight (plus related health issues) lose weight. About 493 participants received either the drug or a placebo, along with diet and exercise advice, for 28 weeks. The main goal was to see how much weight they lost and if the drug was safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

493 people

The number who actually took part.

Started

Dec 2024

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female participants having body mass index (BMI) ≥30.0 kg/m2 or BMI ≥27.0 kg/m2 with the presence of at least one of the following comorbidities: hypertension or dyslipidemia (treated or untreated). * A female participant is eligible to participate if she is: * A woman of nonchildbearing potential. OR * A woman of childbearing potential (WOCBP) who is not pregnant, does not intend to be pregnant, not lactating and is willing to use highly effective contraceptive methods (as required by local regulation or practice) throughout the trial and for 10 weeks after the last injection of the investigational medicinal product (IMP). * Ability to comply with the protocol requirements including self-administration of IMP with vial and syringe. Exclusion Criteria: * Glycated hemoglobin (HbA1c) ≥48 mmol/mol (6.5%), as measured at screening. * History of type 1 or type 2 diabetes mellitus. * Treatment with glucose lowering agent(s) within 90 days prior to screening. * A self-reported change in body weight \>5% within 90 days prior to screening. * Treatment with any medication (prescribed or over-the-counter) or alternative remedies (herbal or nutritional supplements) intended to promote weight loss within 6 months prior to screening. * Previous or planned (during the trial period) obesity treatment with surgery or a body weight loss device. However, liposuction or surgical removal of fat depots more than 1 year prior to screening or device-based interventions (e.g. sleeve, banding or similar) that have been removed more than 6 months prior to screening, are allowed. * Uncontrolled thyroid disease defined as thyroid stimulating hormone \>4.20 mIU/L or \<0.27 mIU/L as measured by the central laboratory at screening. * Lifetime history of a suicidal attempt. * History of major depressive disorder or other severe psychiatric disorders (e.g. schizophrenia or bipolar disorder). * Estimated glomerular filtration rate value \<60.0 mL/min/1.73m2, calculated by the Chronic Kidney Disease-Epidemiology (CKD-EPI) Creatinine Equation17, measured at screening. * Impaired liver function, defined as alanine aminotransferase and/or aspartate aminotransferase ≥2.0 times or bilirubin \>1.5 times upper normal limit, measured at screening. * Presence or history of acute or chronic pancreatitis. * Known clinically significant gastric emptying abnormality (for example, severe gastroparesis or gastric outlet obstruction) or chronic treatment that affects gastrointestinal (GI) motility. * Presence or history of cardiovascular disease including stable and unstable angina pectoris, myocardial infarction, transient ischemic attack, stroke, cardiac decompensation. * Presence or history of clinically significant arrhythmias or clinically significant conduction disorders. * Known or suspected hypersensitivity to amylin analogs or related products. * History of malignant neoplasms (except for basal or squamous cell skin cancer) within 5 years prior to screening. * Known or suspected abuse of alcohol or recreational drugs. * Participant previously treated with petrelintide or any other amylin analog.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity

Contacts and locations

Locations

  • AMR Norman

    Norman, Oklahoma, 73069, United States

  • AMR Wichita East

    Wichita, Kansas, 67226, United States

  • Alliance For Multispecialty Research, LLC

    Lexington, Kentucky, 40509, United States

  • Alliance for Multispecialty Research

    Knoxville, Tennessee, 37909, United States

  • Altoona Center for Clinical Research - Research

    Duncansville, Pennsylvania, 16635, United States

  • CHEAR Center LLC

    The Bronx, New York, 10455, United States

  • Century Research LLC

    Miami, Florida, 33155, United States

  • Clinical Research Center of Florida

    Pompano Beach, Florida, 33060-6977, United States

  • Clinical Trials of Texas, LLC., dba Flourish Research

    San Antonio, Texas, 78229, United States

  • ETG Siedlce

    Siedlce, Masovian Voivodeship, 08-110, Poland

  • ETG Warszawa

    Warsaw, Masovian Voivodeship, 02-677, Poland

  • Excel Medical Clinical Trials, LLC

    Boca Raton, Florida, 33434, United States

  • Fundatia Dr Victor Babes

    Bucharest, 030303, Romania

  • FutureMeds Targowek

    Warsaw, Masovian Voivodeship, 03-291, Poland

  • FutureMeds Warszawa Centrum

    Warsaw, Masovian Voivodeship, 00-215, Poland

  • Futuremeds Olsztyn

    Olsztyn, Warmian-Masurian Voivodeship, 10-165, Poland

  • Great Lakes Clinical Trials LLC dba Flourish Research

    Chicago, Illinois, 60640, United States

  • Innovative Research of West Florida, Inc.

    Clearwater, Florida, 33756, United States

  • Institutul Clinic Fundeni

    Bucharest, 022328, Romania

  • Institutul De Pneumoftiziologie Marius Nasta

    Bucharest, 050159, Romania

  • Institutul National de Endocrinologie C I Parhon

    Bucharest, 011863, Romania

  • Javara Inc

    Charlotte, North Carolina, 28210, United States

  • Krakowskie Centrum MedyczneSp.z o.o

    Krakow, Lesser Poland Voivodeship, 31-501, Poland

  • Lucas Research, Inc.

    New Bern, North Carolina, 28562, United States

  • Manaasas Clinical Research Center

    Manassas, Virginia, 20110, United States

  • Mercury Street Medical Group, PLLC

    Butte, Montana, 59701, United States

  • Palm Beach Research Center

    West Palm Beach, Florida, 33409, United States

  • Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych i Administracji

    Warsaw, Masovian Voivodeship, 02-507, Poland

  • PharmQuest Life Sciences, LLC

    Greensboro, North Carolina, 27408, United States

  • Spitalul Clinic Judetean de Urgenta Sf Apostol Andrei Constanta

    Constanța, 900591, Romania

  • Top Diabet

    Craiova, Dolj, 200515, Romania

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35294, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.